214 related articles for article (PubMed ID: 21501598)
1. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond.
De Clercq E
Biochem Pharmacol; 2011 Jul; 82(2):99-109. PubMed ID: 21501598
[TBL] [Abstract][Full Text] [Related]
2. The Holý Trinity: the acyclic nucleoside phosphonates.
De Clercq E
Adv Pharmacol; 2013; 67():293-316. PubMed ID: 23886004
[TBL] [Abstract][Full Text] [Related]
3. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge.
De Clercq E
Biochem Pharmacol; 2007 Apr; 73(7):911-22. PubMed ID: 17045247
[TBL] [Abstract][Full Text] [Related]
4. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines.
De Clercq E; Andrei G; Balzarini J; Leyssen P; Naesens L; Neyts J; Pannecouque C; Snoeck R; Ying C; Hocková D; Holý A
Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):331-41. PubMed ID: 16247948
[TBL] [Abstract][Full Text] [Related]
5. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.
De Clercq E
Expert Rev Anti Infect Ther; 2003 Jun; 1(1):21-43. PubMed ID: 15482100
[TBL] [Abstract][Full Text] [Related]
6. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.
De Clercq E
Clin Microbiol Rev; 2003 Oct; 16(4):569-96. PubMed ID: 14557287
[TBL] [Abstract][Full Text] [Related]
7. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.
Hostetler KY
Antiviral Res; 2009 May; 82(2):A84-98. PubMed ID: 19425198
[TBL] [Abstract][Full Text] [Related]
8. Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia.
Andrei G; Topalis D; De Schutter T; Snoeck R
Antiviral Res; 2015 Feb; 114():21-46. PubMed ID: 25446403
[TBL] [Abstract][Full Text] [Related]
9. The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonín Holý, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death.
De Clercq E
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146783
[TBL] [Abstract][Full Text] [Related]
10. The acyclic nucleoside phosphonates (ANPs): Antonín Holý's legacy.
De Clercq E
Med Res Rev; 2013 Nov; 33(6):1278-303. PubMed ID: 23568857
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
Painter GR; Almond MR; Trost LC; Lampert BM; Neyts J; De Clercq E; Korba BE; Aldern KA; Beadle JR; Hostetler KY
Antimicrob Agents Chemother; 2007 Oct; 51(10):3505-9. PubMed ID: 17646420
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication.
Keith KA; Hitchcock MJ; Lee WA; Holý A; Kern ER
Antimicrob Agents Chemother; 2003 Jul; 47(7):2193-8. PubMed ID: 12821467
[TBL] [Abstract][Full Text] [Related]
13. Application of kinase bypass strategies to nucleoside antivirals.
Ray AS; Hostetler KY
Antiviral Res; 2011 Nov; 92(2):277-91. PubMed ID: 21878354
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy of the acquired immune deficiency syndrome (AIDS): acyclic nucleoside phosphonate analogues.
De Clercq E
Int J Immunopharmacol; 1991; 13 Suppl 1():91-8. PubMed ID: 1823910
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir disoproxil fumarate for the treatment of hepatitis B infection.
Adusumilli S
Drugs Today (Barc); 2009 Sep; 45(9):679-85. PubMed ID: 19956809
[TBL] [Abstract][Full Text] [Related]
16. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy.
Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK
Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414
[TBL] [Abstract][Full Text] [Related]
17. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective.
De Clercq E
Antiviral Res; 2007 Jul; 75(1):1-13. PubMed ID: 17116336
[TBL] [Abstract][Full Text] [Related]
18. The discovery of antiviral agents: ten different compounds, ten different stories.
De Clercq E
Med Res Rev; 2008 Nov; 28(6):929-53. PubMed ID: 18438800
[TBL] [Abstract][Full Text] [Related]
19. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections.
De Clercq E
Intervirology; 1997; 40(5-6):295-303. PubMed ID: 9675635
[TBL] [Abstract][Full Text] [Related]
20. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro.
Hartline CB; Gustin KM; Wan WB; Ciesla SL; Beadle JR; Hostetler KY; Kern ER
J Infect Dis; 2005 Feb; 191(3):396-9. PubMed ID: 15633099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
